Page last updated: 2024-08-17

spironolactone and angiotensin i

spironolactone has been researched along with angiotensin i in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (20.00)	18.2507
2000's	2 (40.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Igarashi, Y; Kubota, A; Nakagawa, Y; Nasuda, K; Natsume, H; Ogawa, H; Takeuchi, H; Toya, K	1
Farquharson, CA; Struthers, AD	1
Boomsma, F; Lok, DJ; Plokker, HW; van de Wal, RM; van der Horst, FA; van Gilst, WH; van Veldhuisen, DJ; Voors, AA	1
Alves, PH; Castro, CH; Colugnati, DB; Macedo, LM; Mendes, EP; Nunes, AD; Pedrino, GR; Santos, RA; Souza, AP	1
Casarini, DE; Sanches Aragão, D; Stoll, D; Yokota, R	1

Trials

1 trial(s) available for spironolactone and angiotensin i

Article	Year
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation, 2000, Feb-15, Volume: 101, Issue:6 Topics: Aged; Angiotensin I; Angiotensin II; Chronic Disease; Cross-Over Studies; Diuretics; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Forearm; Heart Failure; Humans; Male; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Spironolactone; Vasodilation	2000

Article

Year

Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.

Circulation, 2000, Feb-15, Volume: 101, Issue:6

Topics: Aged; Angiotensin I; Angiotensin II; Chronic Disease; Cross-Over Studies; Diuretics; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Forearm; Heart Failure; Humans; Male; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Spironolactone; Vasodilation

2000

Other Studies

4 other study(ies) available for spironolactone and angiotensin i

Article	Year
Long-term follow-up of a girl with the neonatal form of Bartter's syndrome. Endocrine journal, 1997, Volume: 44, Issue:2 Topics: Angiotensin I; Angiotensin II; Bartter Syndrome; Female; Follow-Up Studies; Growth; Humans; Indomethacin; Infant; Potassium; Spironolactone	1997
Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. International journal of cardiology, 2006, Jan-26, Volume: 106, Issue:3 Topics: Aged; Aged, 80 and over; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Feedback, Physiological; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Peptidyl-Dipeptidase A; Renin; Renin-Angiotensin System; Spironolactone	2006
Influence of antihypertensive drugs on aortic and coronary effects of Ang-(1-7) in pressure-overloaded rats. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2017, Mar-23, Volume: 50, Issue:4 Topics: Amlodipine; Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta, Abdominal; Blood Pressure; Calcium Channel Blockers; Captopril; Coronary Vessels; Losartan; Male; Mineralocorticoid Receptor Antagonists; Models, Animal; Peptide Fragments; Rats, Wistar; Reproducibility of Results; Spironolactone; Time Factors; Vasoconstriction; Vasodilation	2017
Both aldosterone and spironolactone can modulate the intracellular ACE/ANG II/AT1 and ACE2/ANG (1-7)/MAS receptor axes in human mesangial cells. Physiological reports, 2019, Volume: 7, Issue:11 Topics: Aldosterone; Angiotensin I; Angiotensin-Converting Enzyme 2; Cells, Cultured; Glycosylation; Humans; Mesangial Cells; Mineralocorticoid Receptor Antagonists; Peptide Fragments; Peptidyl-Dipeptidase A; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptor, Angiotensin, Type 1; Receptors, G-Protein-Coupled; Spironolactone; Vesicular Transport Proteins	2019